Immunitybio, Inc. (IBRX) — 8-K Filings

8-K Filings (24)

• ImmunityBio Files 8-K with Financial Updates — Apr 9, 2026 Risk: low
  ImmunityBio, Inc. filed an 8-K on April 9, 2026, reporting its financial results and condition. The filing includes exhibits such as financial statements and a
• ImmunityBio Files 8-K: Regulation FD & Exhibits — Apr 6, 2026 Risk: medium
  ImmunityBio, Inc. filed an 8-K on April 6, 2026, reporting under Regulation FD Disclosure and Financial Statements and Exhibits. The filing includes an exhibit
• ImmunityBio Files 8-K: Material Agreement and Financial Updates — Mar 31, 2026 Risk: medium
  On March 30, 2026, ImmunityBio, Inc. entered into a material definitive agreement, creating a direct financial obligation. The company also made a Regulation FD
• ImmunityBio Files 8-K: Material Agreement, Other Events — Dec 29, 2025 Risk: medium
  On December 23, 2025, ImmunityBio, Inc. filed an 8-K report detailing a material definitive agreement. The filing also included other events and financial state
• ImmunityBio Board Changes and Filings — Dec 15, 2025 Risk: medium
  ImmunityBio, Inc. announced on December 10, 2025, a change in its board of directors, with the resignation of Dr. Patrick Soon-Shiong and the appointment of Dr.
• 8-K Filing — Dec 12, 2025
• 8-K Filing — Nov 5, 2025
• ImmunityBio Files 8-K: Other Events & Financials — Aug 8, 2025 Risk: low
  ImmunityBio, Inc. filed an 8-K on August 8, 2025, reporting other events and financial statements. The company, formerly known as NantKwest, Inc., Conkwest, Inc
• ImmunityBio Files 8-K: Material Agreement, Financials — Jul 25, 2025 Risk: medium
  ImmunityBio, Inc. announced on July 24, 2025, that it entered into a material definitive agreement. The company also disclosed its results of operations and fin
• ImmunityBio Files 8-K on Director/Officer Changes & Voting Matters — Jun 20, 2025 Risk: medium
  ImmunityBio, Inc. filed an 8-K on June 20, 2025, reporting events as of June 18, 2025. The filing covers the departure of directors, election of directors, appo
• ImmunityBio Files 8-K: Other Events & Financials — May 5, 2025 Risk: low
  ImmunityBio, Inc. filed an 8-K on May 5, 2025, reporting other events and financial statements. The company, formerly known as NantKwest, Inc., Conkwest, Inc.,
• ImmunityBio Files 8-K on Financials — Apr 15, 2025 Risk: low
  ImmunityBio, Inc. filed an 8-K on April 15, 2025, reporting on its financial condition and results of operations. The filing does not contain specific financial
• ImmunityBio, Inc. Files 8-K with Material Agreement — Apr 8, 2025 Risk: medium
  On April 7, 2025, ImmunityBio, Inc. entered into a material definitive agreement. The filing also includes Regulation FD disclosures and financial statements an
• ImmunityBio Changes Auditors to PricewaterhouseCoopers — Mar 19, 2025 Risk: medium
  ImmunityBio, Inc. filed an 8-K on March 19, 2025, to report a change in its certifying accountant. The company has appointed PricewaterhouseCoopers LLP as its n
• ImmunityBio Announces Board and Executive Changes — Feb 13, 2025 Risk: medium
  ImmunityBio, Inc. announced on February 7, 2025, changes in its board of directors and executive compensation arrangements. The filing details the departure of
• ImmunityBio Files 8-K: Board and Compensation Changes — Feb 7, 2025 Risk: medium
  ImmunityBio, Inc. filed an 8-K on February 7, 2025, reporting changes in its board of directors and executive compensation arrangements. The filing details the
• ImmunityBio Enters Material Definitive Agreement — Dec 11, 2024 Risk: medium
  On December 10, 2024, ImmunityBio, Inc. entered into a material definitive agreement, the details of which are not fully disclosed in this filing. The company a
• ImmunityBio Files 8-K: Financial Statements and Exhibits — Dec 10, 2024 Risk: low
  On December 10, 2024, ImmunityBio, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating a routine disclosure ra
• ImmunityBio Files 8-K: Other Events & Financials — Nov 19, 2024 Risk: low
  ImmunityBio, Inc. filed an 8-K on November 19, 2024, reporting other events and financial statements. The company, formerly known as NantKwest, Inc., is incorpo
• ImmunityBio Files 8-K for Material Definitive Agreement — Jul 18, 2024 Risk: medium
  ImmunityBio, Inc. entered into a Material Definitive Agreement on July 13, 2024. The filing does not disclose specific details of the agreement, its counterpart
• ImmunityBio Files 8-K for Shareholder Votes and Financials — Jun 12, 2024 Risk: low
  ImmunityBio, Inc. filed an 8-K on June 11, 2024, to report on matters submitted to a vote of security holders and financial statements. The filing details the c
• ImmunityBio to Acquire Atara Biotherapeutics for $1B — Apr 23, 2024 Risk: medium
  ImmunityBio, Inc. announced on April 22, 2024, that it has entered into a definitive agreement to acquire Atara Biotherapeutics, Inc. for approximately $1.0 bil
• ImmunityBio Amends Officer Compensation, Code of Ethics — Feb 26, 2024 Risk: low
  ImmunityBio, Inc. filed an 8-K on February 26, 2024, reporting an event that occurred on February 22, 2024. The filing pertains to changes in compensatory arran
• ImmunityBio Reports New Debt, Equity Sales, Material Agreement — Jan 2, 2024
  ImmunityBio, Inc. filed an 8-K on January 2, 2024, reporting events from December 29, 2023, including entering a material definitive agreement, creating a direc

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX